Literature DB >> 22526433

A case of atrioventricular block (Wenckebach type) induced by sugammadex.

Yoshimune Osaka, Naho Shimada, Masaaki Satou, Takahiro Masuda, Takeshi Ando, Yuuki Kozono, Muneaki Shimada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22526433     DOI： 10.1007/s00540-012-1390-x

Source DB:  PubMed          Journal:  J Anesth        ISSN： 0913-8668            Impact factor:   2.078


× No keyword cloud information.
  5 in total

1.  Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.

Authors:  Pieter-Jan de Kam; Jacqueline van Kuijk; Marita Prohn; Torben Thomsen; Pierre Peeters
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.

Authors:  Ozlem Sacan; Paul F White; Burcu Tufanogullari; Kevin Klein
Journal:  Anesth Analg       Date:  2007-03       Impact factor: 5.108

3.  Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.

Authors:  Harald J Sparr; Karel M Vermeyen; Anton M Beaufort; Henk Rietbergen; Johannes H Proost; Vera Saldien; Corinna Velik-Salchner; J Mark K H Wierda
Journal:  Anesthesiology       Date:  2007-05       Impact factor: 7.892

4.  Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.

Authors:  Hans D de Boer; Jacques J Driessen; Marco A E Marcus; Hans Kerkkamp; Marten Heeringa; Markus Klimek
Journal:  Anesthesiology       Date:  2007-08       Impact factor: 7.892

5.  Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.

Authors:  Friedrich K Pühringer; Christopher Rex; Andreas W Sielenkämper; Casper Claudius; Per Bo Larsen; Martine E Prins; Matthias Eikermann; Karin S Khuenl-Brady
Journal:  Anesthesiology       Date:  2008-08       Impact factor: 7.892
  5 in total
  7 in total

1.  Sugammadex Use in a Patient with Wolff-Parkinson-White (WPW) Syndrome.

Authors:  Sevtap Hekimoğlu Şahin; İlhan Öztekin; Aytuna Kuzucuoğlu; Ayça Aslanoğlu
Journal:  Balkan Med J       Date:  2015-07-01       Impact factor: 2.021

Review 2.  Atrio-ventricular Block Following Neostigmine-Glycopyrrolate Reversal in Non-heart Transplant Patients: Case Report.

Authors:  Njinkeng J Nkemngu; Joel N Tochie
Journal:  Anesth Prog       Date:  2018

3.  Bradycardia in a Pediatric Heart Transplant Recipient: Is It the Sugammadex?

Authors:  Adele King; Aymen Naguib; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Sep-Oct

4.  Heart Rate Changes Following the Administration of Sugammadex to Infants and Children With Comorbid Cardiac, Cardiovascular, and Congenital Heart Diseases.

Authors:  Jordan Arends; Richard Hubbard; Shabana Z Shafy; Mohammed Hakim; Stephani S Kim; Dmitry Tumin; Joseph D Tobias
Journal:  Cardiol Res       Date:  2020-08-01

Review 5.  Asystole following neuromuscular blockade reversal in cardiac transplant patients.

Authors:  Njinkeng J Nkemngu
Journal:  Ann Card Anaesth       Date:  2017 Jul-Sep

6.  Cardiovascular adverse effects of sugammadex.

Authors:  Mukul Chandra Kapoor
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2020-09-29

7.  [Severe bradycardia and asystole associated with sugammadex: case report].

Authors:  Catarina Oliveira; Catarina Marques; Vânia Simões; Leina Spencer; Rita Poeira; Margarida Casteleira
Journal:  Braz J Anesthesiol       Date:  2018-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.